Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists

European Journal of Pharmacology

Volumn 577, Issue 1-3, 2007, Pages 78-86

  Sundqvist, Monika ^a   Kristensson, Elin ^a   Adolfsson, Rebecka ^a   Leffler, Agnes ^a   Ahlstedt, Ingela ^a   Engberg, Susanna ^a   Drmota, Tomas ^a   Sigfridsson, Kalle ^a   Jussila, Rainer ^a   de Verdier, Jennie ^a   Novén, Anna ^a   Johansson, Anders ^a   Påhlman, Ingrid ^a   von Mentzer, Bengt ^a   Lindström, Erik ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Gerbil foot tap; Neurokinin; Senktide; Tachykinin receptor; Tachykinin receptor antagonist

Indexed keywords

3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 5 AMINOVALERYLSUBSTANCE P [7-11][9 PROLINE 10 (N METHYLLEUCINE)]; PROLINE 7 NEUROKININ B; RADIOLIGAND; SAREDUTANT; SENKTIDE; TACHYKININ RECEPTOR AGONIST; TACHYKININ RECEPTOR ANTAGONIST; TALNETANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN SLICE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CHO CELL; CONTROLLED STUDY; DRUG BINDING; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; EVOKED RESPONSE; GERBIL; HINDLIMB; LEG MOVEMENT; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; BRAIN; CALCIUM; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOT; GERBILLINAE; INJECTIONS, INTRAVENTRICULAR; MALE; NEUROKININ A; PEPTIDE FRAGMENTS; PIPERIDINES; QUINOLINES; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; RECEPTORS, NEUROKININ-3; SUBSTANCE P;

EID: 35448937668     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.08.042     Document Type: Article

References (45)

1. Advenier C., Rouissi N., Nguyen Q.T., Emonds-Alt X., Breliere J.-C., Neliat G., Naline E., and Regoli D. Neurokinin A (NK2) receptor revisited with SR48968, a potent non-peptide antagonist. Biochem. Biophys. Res. Commun. 184 (1992) 1418-1424
2. Appell K.C., Fragale B.J., Loscig J., Singh S., and Tomczuk B.E. Antagonists that demonstrate species differences in neurokinin-1 receptors. Mol. Pharmacol. 41 (1992) 772-778
3. Ballard T.M., Sänger S., and Higgins G.A. Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist. Eur. J. Pharmacol. 412 (2001) 255-264
4. Beaujouan J.-C., Saffroy M., Torrens Y., and Glowinski J. Different subtypes of tachykinin NK1 receptor binding sites are present in the rat brain. J. Neurochem. 75 (2000) 1015-1026
5. Beresford I.J.M., Birch P.J., Hagan R.M., and Ireland S.J. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br. J. Pharmacol. 104 (1991) 292-293
6. Bergström M., Fasth K.J., Kilpatrick G., Ward P., Cable K.M., Wipperman M.D., Sutherland D.R., and Långström B. Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171-PET studies in rhesus monkey. Neuropharmacology 39 (2000) 664-670
7. Bristow L.J., and Young L. Chromodacryorrhea and repitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils. Eur. J. Pharmacol. 253 (1994) 245-252
8. Dableh L.J., Yashpal K., Rochford J., and Henry J.L. Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur. J. Pharmacol. 507 (2005) 99-105
9. Duffy R.A. Potential therapeutic targets for neurokinin-1 receptor antagonists. Exp. Opin. Emerg. Drugs 9 (2004) 9-21
10. Duffy R.A., Varty G.B., Morgan C.A., and Lachowicz J.E. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioural effects of NK1 antagonists. J. Pharmacol. Exp. Ther. 301 (2002) 536-542
11. Emonds-Alt X., Bichon D., Ducoux J.P., Heaulme M., Miloux B., Poncelet M., Proietto V., Van Broeck D., Vilain P., Neliat G., Soubrié P., Le Fur G., and Breliére J.C. SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci. 56 (1995) PL27-PL32
12. Emonds-Alt X., Proietto V., Steinberg R., Advenier C., Daoui S., Naline E., Gueudet C., Michaud J.-C., Oury-Donat F., Poncelet M., Vilain P., Le Fur G., Maffrand J.-P., Soubrié P., and Pascal M. Biochemical and pharmacological activities of SSR146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can. J. Physiol. Pharmacol. 80 (2002) 482-488
13. Engberg S., Ahlstedt I., Leffler A., Lindström E., Kristensson E., Svensson A., Påhlman I., Johansson A., Drmota T., and von Mentzer B. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors. Biochem. Pharmacol. 73 (2007) 259-269
14. Giuliani S., and Maggi C.A. Effect of SR 142801 on nitric oxide-dependent and independent responses to tachykinin NK3 receptor agonists in isolated guinea-pig colon. Naunyn-Schmiedeberg's Arch. Pharmacol. 352 (1995) 512-519
15. Graham E.A., Turpin M.P., and Stubbs C.M. Characterisation of the tachykinin-induced hindlimb thumping response in gerbils. Neuropeptides 24 (1993) 228-229
16. Griffante C., Carletti R., Andreetta F., and Corsi M. [3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain. Br. J. Pharmacol. 148 (2006) 39-45
17. Hagan R.M., Ireland S.J., Jordan C.C., Beresford I.J.M., Deal M.J., and Ward P. Receptor-selective, peptidase-resistant agonists at neurokinin NK-1 and NK-2 receptors: new tools for investigating neurokinin function. Neuropeptides 19 (1991) 127-135
18. Hale J.J., Mills S.G., MacCoss M., Finke P.E., Cascieri M.A., Sadowski S., Ber E., Chicchi G.G., Kurtz M., Metzger J., Eiermann G., Tsou N.N., Tattersall F.D., Rupniak N.M.J., Williams A.R., Rycroft W., Hargreaves R., and MacIntyre D.E. Structural optimization affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J. Med. Chem. 41 (1998) 4607-4614
19. Haley G.E., and Flynn F.W. Agonist and hypertonic saline-induced trafficking of the NK3-receptors on vasopressin neurons within the paraventricular nucleus of the hypothalamus. Am. J. Physiol. 290 (2006) R1242-R1250
20. Hargreaves R. Imaging substance P receptor antagonists in the living human brain using positron emission tomography. J. Clin. Psychiatry 63 (2002) 18-24
21. Johnson P.J., Bornstein J.C., and Burcher E. Roles of neuronal NK1 and NK3 receptors in synaptic transmission during motility reflexes in the guinea-pig ileum. Br. J. Pharmacol. 124 (1998) 1375-1384
22. Jung M., Michaud J.C., Steinberg R., Barnouin C., Hayar A., Mons G., Souilhac J., Emonds-Alt X., Soubrié P., and Le Fur G. Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin NK3 receptor stimulation. Neuroscience 74 (1996) 403-414
23. Khan S., Whelpton R., and Michael-Titus A.T. Evidence for modulatory effects of substance P fragments (1-4) and (8-11) on endogenous dopamine outflow in rat striatal slices. Neurosci. Lett. 205 (1996) 33-36
24. Langlois X., Wintmolders C., te Riele P., Leysen J.E., and Jurzak M. Detailed distribution of neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study. Neuropharmacology 40 (2001) 242-253
25. Lindfors L., Skantze P., Skantze U., Rasmusson M., Zackrisson A., and Olsson U. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald Ripening. Langmuir 22 (2006) 906-910
26. Maggi C.A. Tachykinins in the autonomic nervous system. Pharm. Res. 33 (1996) 161-170
27. Maggi C.A., Petacchini R., Rovero P., and Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J. Auton. Pharm. 13 (1993) 23-93
28. McLean S., Ganong A., Seymour P.A., Snider R.M., Desai M.C., Rosen T., Bryce D.K., Longo K.P., Reynolds L.S., and Robinson G. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J. Pharmacol. Exp. Ther. 267 (1993) 472-479
29. Medhurst A.D., Parsons A.A., Roberts J.C., and Hay D.W.P. Characterization of NK3 receptors in rabbit isolated iris sphincter muscle. Br. J. Pharmacol. 120 (1997) 93-101
30. Megens A.A.H.P., Ashton D., Vermeire J.C.A., Vermonte P.C.M., Hens K.A., Hillen L.C., Fransen J.F., Mahieu M., Heylen L., Leysen J.E., Jurzak M.R., and Janssens F. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist. J. Pharmacol. Exp. Ther. 302 (2002) 696-709
31. Pennefather J.N., Alessandro L., Candenas M.L., Patak E., Pinto F.M., and Maggi C.A. Tachykinins and tachykinin receptors: a growing family. Life Sci. 74 (2004) 1445-1463
32. Petitet F., Saffroy M., Torrens Y., Lavielle S., Chassang G., Loeuillet D., Glowinski J., and Beaujouan J.-C. Possible existence of a new tachykinin receptor subtype in the guinea pig ileum. Peptides 13 (1992) 383-388
33. Quartara L., and Maggi C.A. The tachykinin NK1 receptor. Part I: ligands and mechanism of cellular activation. Neuropeptides 31 (1997) 537-563
34. Rupniak N.M.J., and Williams A.R. Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. Eur. J. Pharmacol. 265 (1994) 179-183
35. Rupniak N.M.J., Tattersall F.D., Williams A.R., Rycroft W., Carlson E.J., Cascieri M.A., Sadowski S., Ber E., Hale J.J., Mills S.G., MacCoss M., Seward E., Huscroft I., Owen S., Swain C.J., Hill R.G., and Hargreaves R.J. In vitro and in vivo predictors of the anti-emetic activity of tachylinin NK1 receptor antagonists. Eur. J. Pharmacol. 326 (1997) 201-209
36. Rupniak N.M.J., Webb J.K., Fisher A., Smith D., and Boyce S. The substance P (NK1) receptor antagonist L-760735 inhibits fear conditioning in gerbils. Neuropharmacol. 44 (2003) 516-523
37. Rupinak N.M.J., Carlsson E.J., Shepard S., Bentley G., Williams A.R., Hill A., Swain C., Mills S.G., Salvo J.D., Kilburn R., Cascieri M.A., Kurtz M.M., Tsao K.-L., Gould S.L., and Chicchi G.G. Comparision of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608. Neuropharmacology 45 (2003) 231-241
38. Salomé N., Stemmelin J., Cohen C., and Griebel G. Selective blockade of NK2 or NK3 receptors produces anxiolytic and antidepressant effects in gerbils. Pharmacol. Biochem. Behav. 83 (2006) 533-539
39. Sarau H.M., Griswold D.E., Potts W., Foley J.J., Schmidt D.B., Webb E.F., Martin L.D., Brawner M.E., Elshourbagy N.A., Medhurst A.D., Giardina G.A., and Hay D.W.P. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J. Pharm. Exp. Ther. 281 (1997) 1303-1311
40. Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur. J. Pharmacol. 375 (1999) 51-60
41. Severini C., Improta G., Falconieri-Erspamer G., Salvadori S., and Erspamer V. The tachykinin peptide family. Pharm. Rev. 54 (2002) 285-322
42. Smith D.W., Hewson L., Fuller P., Williams A.R., Wheeldon A., and Rupniak N.M.J. The substance P antagonist L-760735 inhibits stress-induced NK1 receptor internalization in the basolateral amygdala. Brain Res. 848 (1999) 90-95
43. Steinberg R., Alonso R., Rouquier L., Desvignes C., Michaud J.C., Cudennec A., Lung M., Simiand J., Griebel G., Emonds-Alt X., Le Fur G., and Soubrie P. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization. J. Pharm. Exp. Ther. 303 (2002) 1180-1188
44. Stoessel A.J., Polanski E., and Frydryszak H. Effects of ageing on tachykinin function in the basal ganglia. Brain Res. 632 (1993) 21-28
45. Yip J., and Chahl L.A. Localization of fos-like immunoreactivity induced by the NK3 tachykinin receptor agonist, senktide, in the guinea pig brain. Br. J. Pharmacol. 122 (1997) 715-725